Oramed Pharmaceuticals

A clinical-stage pharmaceutical company developing oral drug delivery systems for injectable treatments.

Biotechnology

Public on NASDAQ on Apr, 2006
Public on TASE on Jul, 2017

Public Jerusalem, Israel Founded 2006

Last updated 2026-09-06

Went public on NASDAQ (ORMP), Feb 2013
Raised $100M Follow-on PO, Sep 2021
Raised $75M Follow-on PO, Mar 2024

Total raised

$347.0M

Last: Public Offering 2021-11

Stage

Public

Founded

2006

Headcount

Jerusalem, Israel

Sector

Biotechnology

Website ↗LinkedIn ↗Registrar ID: 513976712 (Oramed Pharmaceuticals Inc.)

About

Oramed Pharmaceuticals Inc. is a publicly traded company focused on the research and development of oral drug delivery systems, primarily an oral insulin capsule for treating type 2 diabetes. The company's proprietary Protein Oral Delivery (POD™) technology is designed to protect therapeutic proteins from enzymatic breakdown in the gastrointestinal tract and enhance their absorption. Oramed is also developing an oral GLP-1 analog capsule and an oral leptin capsule. The company is transitioning its business model to include strategically operating medical technology businesses through acquiring controlling interests in a portfolio of entities.

Funding history · 11 rounds · $347.0M total

14 events/rounds · $347.0M Total Funding: $17.0M in Private Equity, $400.0M in Public Equity

Mar 2024

Follow-on PO $75.0M EDGAR filing SEC-EDGAR filing SEC-EDGAR 8-K

Nov 2021

Follow-on PO $50.0M EDGAR filing SEC-EDGAR filing SEC-EDGAR 42…

Sep 2021

Follow-on PO $100.0M EDGAR filing SEC-EDGAR filing SEC-EDGAR 8-K

Jun 2021

Follow-on PO $28.0M EDGAR filing SEC-EDGAR filing SEC-EDGAR 8-K

Dec 2020

Follow-on PO $40.0M EDGAR filing SEC-EDGAR filing SEC-EDGAR 8-K

Mar 2020

Follow-on PO $21.0M EDGAR filing SEC-EDGAR filing SEC-EDGAR 42…

Sep 2019

Follow-on PO $15.0M EDGAR filing SEC-EDGAR filing SEC-EDGAR 8-K

Jul 2015

Undisclosed Round $12.0M fiercebiotech.com ↗

★ Sinopharm Capital Management

Nov 2014

Undisclosed Round $5.0M fiercebiotech.com ↗

★ Guangxi Wuzhou Zhongheng Group

Jun 2013

Grant $263K fiercepharma.com ↗

★ Office of the Chief Scientist (OCS) of Israel

Dec 2010

Grant $783K globes.co.il ↗

★ Office of the Chief Scientist (OCS) of Israel

Headcount over time

13 employees (2026-09) · 1 point

Offices

Jerusalem, Israel · HQ / main office

Show all offices (1 more)

New York, United States

Q&A

What is Oramed Pharmaceuticals' primary focus?: Oramed Pharmaceuticals is a clinical-stage pharmaceutical company that develops oral drug delivery systems for treatments typically administered via injection. Their main product is an oral insulin capsule for type 2 diabetes.
What is Oramed Pharmaceuticals' current public status?: Oramed Pharmaceuticals is a public company, listed on NASDAQ since April 2006 and on TASE since July 2017.
What is Oramed Pharmaceuticals' proprietary technology?: Oramed Pharmaceuticals utilizes its proprietary Protein Oral Delivery (POD™) technology, designed to protect therapeutic proteins from enzymatic breakdown in the gastrointestinal tract and enhance their absorption.
What was Oramed Pharmaceuticals' most recent funding round?: Oramed Pharmaceuticals completed a Public Offering in March 2024, raising $75,000,000.
What is the employee count for Oramed Pharmaceuticals?: Oramed Pharmaceuticals has an employee count in the 11-50 range.
What is Oramed Pharmaceuticals' strategy regarding medical technology businesses?: Oramed Pharmaceuticals is transitioning its business model to include strategically operating medical technology businesses by acquiring controlling interests in a portfolio of entities.
What was a significant financial event for Oramed Pharmaceuticals in July 2026?: In July 2026, Oramed Pharmaceuticals secured $11,160,000 through a Convertible Debt round.
What recent strategic partnership did Oramed Pharmaceuticals announce in January 2026?: In January 2026, Oramed Pharmaceuticals and Lifeward announced a strategic transaction that will transfer Oramed's oral drug delivery platform (POD™ Technology) to Lifeward, positioning Oramed as a significant shareholder in the new diversified biomedical innovation company.
What was a key development for Oramed Pharmaceuticals in June 2026?: In June 2026, Oramed Pharmaceuticals announced its inclusion in the U.S. small cap Russell 2000 and Russell 3000 Indexes.

Team · 21

Nadav Kidron

Founder · CEO, President & Executive Chairman

Miriam Kidron

Founder · Chief Scientific Officer & Director

Josh Hexter

Chief Operating and Business Officer

Avraham Gabay

Chief Financial Officer, Treasurer, Secretary and Principal Accounting Officer

Michael Rabinowitz

Chief Commercial Officer

Netanel Derovan

Chief Legal Officer (General Counsel) and Company Secretary

Benjamin Shapiro

Independent Director

Daniel Aghion

Independent Director

Yehuda Reznick

Independent Director

Arie Mayer

Independent Director

Xiaoming Gao

Director

Robert Henry